Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous

NCT03213665

Clinical Trial Information


Trial Number: NCT03213665 (ClinicalTrials.gov)
Disease Type:
  • CNS Neoplasm (Primary Tumor) - Miscellaneous
  • CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex"
Study ID:
APEC1621C
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT03213691

Clinical Trial Information


Trial Number: NCT03213691 (ClinicalTrials.gov)
Disease Type:
  • CNS Neoplasm (Primary Tumor) - Miscellaneous
  • CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Study ID:
APEC1621E
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT03578081

Clinical Trial Information


Trial Number: NCT03578081 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Miscellaneous Neoplasm - Carcinoma, Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
OLANZAPINE WITH OR WITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Study ID:
A221602
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT01817075

Clinical Trial Information


Trial Number: NCT01817075 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Miscellaneous Neoplasm - Other
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Study ID:
ACCL1034
Images are available?:
No
Is this a NCI-MATCH Trial?:
No


Datasets Linked to Trial

Title Description
NCT01817075-D5 NCT01817075-D5: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D5, provides organisms identified from positive blood cultures (Figure 3). The number of rows per patient is dependent on number of organisms submitted.
NCT01817075-D4 NCT01817075-D4: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D4, provides cutaneous adverse event information during the study period (Table 4 & Figure 4). The number of rows per patient is dependent on number of cutaneous adverse events submitted.
NCT01817075-D3 NCT01817075-D3: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D3, provides more detailed information on the cutaneous staphylococci isolates (as mentioned in the text of the manuscript). Data provided for all eligible and evaluable patients (N=174 patients) who submitted baseline and at least 1 follow-up swab (N=1046 swabs). The number of rows per patient is dependent on number of samples submitted.
NCT01817075-D2 NCT01817075-D2: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D2, provides the information for baseline characteristics (Table 1), all primary, secondary and post-hoc analyses (Table 2), general isolate data (Table 3), time to event analysis (Figure 2), Supporting Information (eTables 1-2) and other results reported in the manuscript. Data provided for all eligible patients (N=175) but the analysis is limited to all evaluable patients (N=174, CONSORT06≠Excluded in analysis). There is one row per patient.
NCT01817075-D1 NCT01817075-D1: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D1, provides the information for the consort diagram in the manuscript (Figure 1). Data provided for all enrolled patients (N=177). There is one row per patient.
Subscribe to Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous

Accessibility  |  Disclaimer  |  FOIA  |  HHS Vulnerability Disclosure  |  Privacy & Security

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®